Navigation Links
Solos Endoscopy, Inc. in Final Stages to Upgrade Pink Sheet Status from Limited to Current Information
Date:10/14/2008

BOSTON, Oct. 14 /PRNewswire-FirstCall/ -- Solos Endoscopy, Inc. (OTC Pink Sheets: SNDY) is pleased to announce that the Company is in the final stages to upgrade its status on the Pinksheets Electronic OTC Markets from Limited Information to Current Information. The Company is in the process of completing their Issuer Information Statement, which will be accompanied by an attorney's opinion letter. The Company expects to have its status upgraded by the end of the quarter.

A Pinksheets status of current information indicates that Solos Endoscopy, Inc. will make its current information publicly available through the OTC Disclosure and News Service according to the Pink OTC Markets manual: Guidelines for Providing Adequate Current Information. There are currently 1,111 companies trading under current information as opposed to 521 companies trading under limited information. The 1,111 companies trading under current information represented approximately 65.4% of the total dollar volume traded during the month of December 2007, according to Pinksheets.com.

"By upgrading our status to current information, we are demonstrating to our shareholders that we are working hard to increase the value of our stock as we move forward with our business strategy over the next several months," stated Bob Segersten, President of Solos Endoscopy, Inc.

Please click on the link to view the Guidelines for Providing Adequate Current Information. (http://www.pinksheets.com/content/doc/ps/Disclosure/Guidelines/2.pdf)

About Solos Endoscopy, Inc.:

Solos Endoscopy, Inc. is a healthcare technology company whose mission is to develop and market breakthrough technology, applications, medical devices, and procedural techniques for the screening, diagnosis, treatment and management of medical conditions. Backed by technical support, Solos' sales team can help make the right buying decisions for the hospital, surgery center, or physician office. Additional information is available on the Company's website at: http://www.solosendoscopy.com.

Safe Harbor: This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approval for anticipated actions.


'/>"/>
SOURCE Solos Endoscopy, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Solos Endoscopy, Inc. Implements Strategy to Capitalize on $30 Billion Minimally Invasive Surgical Product Market
2. Sanofi-aventis SoloSTAR(R) Insulin Pen for Lantus and Apidra Receives the Prestigious GOOD DESIGN Award
3. Essilor Finalizes Satisloh Agreement
4. Covance and Lilly Finalize 10-Year, $1.6 Billion Strategic R&D Collaboration
5. 2008 R&D Innovator of the Year & Scientist of the Year Finalists Announced
6. Memory Pharmaceuticals Closes Final Tranche of Equity Financing with The Stanley Medical Research Institute
7. CV Therapeutics Announces Ranexa(R) Named Finalist for Prix Galien USA 2008 Award
8. Prix Galien USA Announces 2008 Final Candidates
9. White Paper Explains Aspects of Testing From Purified Bulk Drug Substance to Sterile Liquid Final Drug Product
10. Daiichi Sankyo and Ranbaxy Confirm Deal Is Binding and Final, Allay Market Rumour and Speculation
11. Wyeth and Impax Announce Final Settlement of Effexor XR Patent Suit
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/7/2017)... (PRWEB) , ... October 06, ... ... years’ experience providing advanced instruments and applications consulting for microscopy and surface ... expertise in application consulting, Nanoscience Analytical offers a broad range of contract ...
(Date:10/7/2017)...  The 2017 Nobel Prize in Chemistry recognizes ... Joachim Frank and Richard Henderson ... (cryo-EM) have helped to broaden the use ... The winners worked with systems manufactured by Thermo ... resolved, three-dimensional images of protein structures that lead ...
(Date:10/6/2017)... ... 2017 , ... On Tuesday, October 24th, ABC² (Accelerate Brain ... adaptive clinical trial for glioblastoma (GBM). The featured speaker will be Dr. Brian ... to the public, but registration is required. , WHAT: ABC² Brain Cancer ...
(Date:10/5/2017)... ... , ... Understanding the microbiome, the millions of bacteria that live in our ... My Future, the newest exhibit on display at the University City Science Center’s Esther ... the lens of the gut microbiome. , Gut Love opens October 12, 2017, ...
Breaking Biology Technology:
(Date:7/20/2017)... , July 20, 2017 Delta (NYSE: DAL ... board any Delta aircraft at Reagan Washington National Airport (DCA). ... Delta launches biometrics to ... Delta,s biometric ... Sky Club is now integrated into the boarding process to allow ...
(Date:6/14/2017)... IBM ) is introducing several innovative partner startups at VivaTech ... startups and global businesses, taking place in Paris ... will showcase the solutions they have built with IBM Watson ... France is one of the most dynamic ... in the number of startups created between 2012 and 2015*, ...
(Date:5/16/2017)... , May 16, 2017   Bridge ... health organizations, and MD EMR Systems , ... development partner for GE, have established a partnership ... Portal product and the GE Centricity™ products, including ... EMR. These new integrations will ...
Breaking Biology News(10 mins):